Following his presentation at the EAACI annual meeting, we were delighted to talk with Prof. Dr. Philippe Gevaert (University of Ghent, Belgium) about targeted endotype therapeutics in severe airway disease.
Questions
1. What are the major unmet needs in the treatment of severe airway disease? (0:04)
2. Could you give is a brief overview of the role of endotypes in airway disease? (1:20)
3.What have been the most promising endotype-driven approaches to date? (3:10)
4.What other emerging therapeutic targets would you like to highlight? (4:25)
5. What are the major challenges to be overcome before endotype-driven therapies can be implemented in routine clinical practice? (6:26)
Speaker disclosure: Philippe Gevaert has served as a speaker and advisor for Ablynx, Argenx, Astra Zeneca, Sanofi, Novartis, Regeneron, Genentech, ALK and Stallergenes-Greer
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the EAACI Digital Congress 2020.
